First Clinical Results After Implantation Of The Evo Viva Icl: 3-Month Data

The EVO Viva Implantable Collamer Lens (ICL) was recently approved for the correction of presbyopia, although reading books without additional visual aids was rarely possible. As part of our quality management, we aimed to evaluate near vision performance when implanting the Viva ICL in the near-dominant eye with a target refraction of -1.5 D.

All surgeries were performed by one surgeon at Breyer-Kaymak-Klabe Eye Surgery and Premium Eyes in Duesseldorf, Germany, member of the International Vision Correction Research Center (IVCRC.net).

An EVO Viva ICL (Staar Surgical) with a target refraction of -1.5 D was implanted in four patients. Preoperative and postoperative examinations included refraction, uncorrected and best-corrected distance and near visual acuity, subjective patient satisfaction, and the defocus curve.

Three months after implantation, all patients showed a significant improvement in uncorrected distance, intermediate, and near visual acuity. The mean change in spherical equivalent was 8.55 D, with high refractive accuracy (100% within ±0.5 D). Patient satisfaction was high, and all patients were able to read a book without correction. No severe complications occurred. The defocus curve objectively confirmed the subjective patient reports by demonstrating a smooth visual transition.

The first clinical experience with the EVO Viva ICL with a target refraction of -1.5 D shows promising refractive results in presbyopic patients, with excellent predictability and high patient satisfaction after three months. The EVO Viva ICL may thus represent an interesting additional option for presbyopia correction alongside PresbyLASIK and IOLs.